TrialJournal of neuro-oncology2019
Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma.
Thomas J Kaley et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
41 papers cite it
this paperpooled itcites it
TrialJournal of neuro-oncology2019
Thomas J Kaley et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.